Article
Oncology
Peifeng Li, Jia Chai, Zi Chen, Yang Liu, Jie Wei, Yixiong Liu, Danhui Zhao, Jing Ma, Kaijing Wang, Xia Li, Yang Shao, Li Gong, Wei Zhang, Shuangping Guo, Qingguo Yan, Mingyang Li, Linni Fan, Zhe Wang
Summary: The study analyzed whole-exome sequencing data of 25 GI-DLBCL patients, identifying genetic oncogenic mutations including TP53, MUC16. GI-DLBCL shows different genetic mutations compared to other DLBCL types, which may influence its clinicopathological characteristics.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Xiuchen Guo, Jingbo Zhang, Jingya Zeng, Yiwei Guo, Lina Zhao
Summary: The study demonstrates that miR-525-5p inhibits the progression of DLBCL through the Myd88/NF-kappa B pathway.
Review
Hematology
Ryan D. Morin, Sarah E. Arthur, Daniel J. Hodson
Summary: The term DLBCL encompasses a diverse collection of tumors, and recent molecular profiling studies have proposed new classification systems to overcome this biological heterogeneity. Challenges include applying these new systems in clinical practice, introducing genomic subtyping and precision medicine into DLBCL, and addressing the implications for current clinical practices and trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Dario Marino, Marco Pizzi, Iuliia Kotova, Ronny Schmidt, Christoph Schroeder, Vincenza Guzzardo, Ilaria Talli, Edoardo Peroni, Silvia Finotto, Greta Scapinello, Angelo Paolo Dei Tos, Francesco Piazza, Livio Trentin, Vittorina Zagonel, Erich Piovan
Summary: This study identifies two proteins that are important for predicting the survival of patients with diffuse large B-cell lymphoma (DLBCL). Additionally, the expression levels of one of these proteins can predict sensitivity to a specific death-inducing drug, suggesting personalized treatment options. The oncogenic function of ETV6 in DLBCL is also highlighted.
Article
Veterinary Sciences
Antonella Fanelli, Laura Marconato, Luca Licenziato, Lucia Minoli, Nicole Rouquet, Luca Aresu
Summary: The aim of this study was to assess the prevalence of POT1 mutations in cDLBCL and investigate their role in the pathogenesis of the tumor. The results showed that POT1 mutations were found in a significant percentage of cDLBCL cases, but no significant associations with clinical and pathological variables or prognosis were observed. However, dogs with POT1 mutations did exhibit higher cellular proliferation levels.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Genetics & Heredity
Tamanna Tasnim Dristy, Al - Rownoka Noor, Puja Dey, Ayan Saha
Summary: This study aims to identify Single Nucleotide Polymorphisms (SNPs) in the SOCS1 gene that are associated with the mortality rate of DLBCL patients and evaluate the effects of SNPs on the structural instability of the SOCS1 protein in DLBCL patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Review
Oncology
Maria Lopez-Santillan, Elixabet Lopez-Lopez, Paula Alvarez-Gonzalez, Garazi Martinez, Javier Arzuaga-Mendez, Irune Ruiz-Diaz, Isabel Guerra-Merino, Angela Gutierrez-Camino, Idoia Martin-Guerrero
Summary: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous and aggressive disease, with some patients requiring new treatment strategies after failing first-line therapy. Mutational analysis may serve as prognostic biomarkers and guide treatment selection.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Immunology
Yu Rebecca Miao, Kaushik Thakkar, Can Cenik, Dadi Jiang, Kazue Mizuno, Chenjun Jia, Caiyun Grace Li, Hongjuan Zhao, Anh Diep, Yu Xu, Xin Eric Zhang, Teddy Tat Chi Yang, Michaela Liedtke, Parveen Abidi, Wing-Sze Leung, Albert C. Koong, Amato J. Giaccia
Summary: This study reveals the distinctive requirements for neutralizing TNF receptor ligands APRIL and BAFF in hematological cancers, and demonstrates that an affinity-enhanced mutant sBCMA-Fc fusion molecule (sBCMA-Fc V3) significantly enhances antitumor activity against both MM and DLBCL. The study also shows an adequate toxicity profile and on-target mechanism of action in nonhuman primate studies.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Review
Oncology
Allison Barraclough, Eliza Hawkes, Laurie H. Sehn, Sonali M. Smith
Summary: Large B-cell lymphoma is the most common lymphoma and has the highest burden of lymphoma-related deaths. Treatment has aimed to achieve a cure with CHOP and rituximab plus CHOP, but not all patients are cured due to the heterogeneity of the disease.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Hematology
Osama Abd El Hameed Ebid, Lobna R. Ezz El Arab, Amr S. Saad, Mai Ezz El Din, Nermeen Mostafa, Menha Swellam
Summary: This study aimed to determine the predictive and prognostic role of MYD88 and TP53 gene mutations in DLBCL. The results showed that mutant MYD88 and TP53 were more accurate in predicting overall mortality and disease progression than the international prognostic index. Mutant MYD88 and TP53 were also associated with worse objective response rates and survival outcomes.
ANNALS OF HEMATOLOGY
(2023)
Article
Immunology
Dan Guo, Lemin Hong, Hao Ji, Yuwen Jiang, Ling Lu, Xinfeng Wang, Hongming Huang
Summary: In this study, target sequencing was performed on primary testicular diffuse large B-cell lymphoma (PT-DLBCL) patients, revealing the mutation landscape and identifying BTG2 mutation as an independent predictor of poor prognosis. An OS predict model of PT-DLBCL patients with high accuracy was constructed.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Oncology
Wei Qin, Di Fu, Qing Shi, Lei Dong, Hongmei Yi, Hengye Huang, Xufeng Jiang, Qi Song, Zhenhua Liu, Shu Cheng, Jinyan Huang, Li Wang, Pengpeng Xu, Weili Zhao
Summary: The clinical and molecular characteristics of localized diffuse large B-cell lymphoma with single nodal or single extranodal involvement in the rituximab era are complex and not fully understood. Analysis of clinical features, genetic aberrations, and tumor immunophenotype can guide personalized treatment for localized DLBCL in the future.
FRONTIERS IN ONCOLOGY
(2021)